ICE Pharma

ICE Pharma manufactures active pharmaceutical ingredients, with a core focus on Ursodeoxycholic Acid (UDCA) for the treatment of liver diseases and gallstones. The company also develops bile acid derivatives used as excipients, nutraceutical ingredients, cell culture media, and intermediates. ICE Pharma provides contract manufacturing for liquid and solid finished dosage forms for branded and generic products. Since October 2019, the company has been owned by Advent International, a global private equity investor. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.